USCOM LIMITED — AGM Information 2022

Nov 9, 2022

==> picture [87 x 36] intentionally omitted <==

==> picture [182 x 45] intentionally omitted <==

FY22 AGM Presentation and Update

• World leading biotech

• FY22 Results

• Products, regulatory and IP

• FY22 Achievements

• FY23 Growth strategies

Prof. Rob Phillips Chairman and CEO, Uscom Limited

ASX: UCM

Nov 10,2022

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Uscom Markets

Milestones

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Uscom Vision

“A great company, with great vision, technology and culture, and a great global opportunity”

==> picture [469 x 234] intentionally omitted <==

Our Team around the world

Uscom has a mission to demonstrate leadership in science and create non-invasive devices to improve clinical care and patient outcomes.

”Uscom has invested in the future at a time when the future is uncertain. Our confidence in our technologies, strategy and people is reflected in the outcomes of FY22 and the prospects for FY23; Uscom has never been in a better position.”

==> picture [94 x 102] intentionally omitted <==

Rik Denicke Zsófia Kertész Teresa Guo Nick Schicht Director of Operations Director of International General Manager at Finance and marketing at Uscom Inc Operations , General Uscom Ltd manager at Uscom Kft Manager at Uscom China

Prof. Rob Phillips CEO of Uscom

==> picture [35 x 11] intentionally omitted <==

----- Start of picture text -----

Ideas
----- End of picture text -----

==> picture [45 x 14] intentionally omitted <==

----- Start of picture text -----

People
----- End of picture text -----

==> picture [45 x 14] intentionally omitted <==

----- Start of picture text -----

Capital
----- End of picture text -----

==> picture [55 x 11] intentionally omitted <==

----- Start of picture text -----

Success
----- End of picture text -----

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Uscom Markets

Milestones

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

==> picture [4 x 4] intentionally omitted <==

Uscom Medical Technology

“Uscom is a world leading ASX listed, advanced medical technology company specialising in cardiovascular and pulmonary monitoring devices, with a global operational footprint and leadership in medical science and technology. Uscom has a global web of ~200 patents and IP applications, and over 600 publications validating the clinical benefits of its technologies.”

• World leading medical technology (ASX:UCM)

• Flagship science and technology in prestige CVP sector

• Multiple products with global regulatory

• Addressing diseases responsible for >75% of all mortality

• 600 publications and multiple global practice guidelines

• Singapore HQ, Chinese manufacturing, global operations

• High margin and IP protected devices

• Expanding product portfolio

• Cash on hand and debt free

• Established growth history

• Positioned for sustained growth

• Partnering for scale and value

==> picture [140 x 140] intentionally omitted <==

==> picture [109 x 72] intentionally omitted <==

==> picture [119 x 84] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

==> picture [97 x 109] intentionally omitted <==

==> picture [45 x 86] intentionally omitted <==

==> picture [83 x 59] intentionally omitted <==

==> picture [145 x 109] intentionally omitted <==

Uscom - The Measure of Life

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Uscom Overview

ASX Listed

Global cardiovascular and pulmonary med tech Visionary and innovative corporate culture

Receipts and Cash

$3.48m total receipts $4.7m cash Debt free

Growth and Margins Historical trend growth 24% CAGR. Huge global addressable markets – 75% of all mortality Margins 75%+

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

Global Vision

Singapore HQ, China manufacture, Sydney, Budapest, UK, US. Hedged for currency and geopolitics Scale and incremental growth strategies/partnerships

Apex Tech and IP

World leading digital med tech, >600 publications, >200 IP submissions, Strong R&D/product pipeline

New Products

New global regulatory and distribution New products and approvals for 2023 Product pipeline forming Foxconn partnership

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Uscom Markets

Milestones

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Uscom Snapshot

Uscom has an international footprint and is prepared for global growth in synch with global recovery

==> picture [38 x 38] intentionally omitted <==

7 Global centres Expanding distribution hubs

Manufacturing sites across 7 countries annual 3 AUD$3.5m receipts (FY22) Australia China Hungary Singapore UK US

==> picture [472 x 180] intentionally omitted <==

----- Start of picture text -----

• London
• Delaware • Budapest • Beijing
• Singapore
• Sydney
• Auckland
----- End of picture text -----

USCOM 1A units 1,500[+] installed globally New products for 10[+] market FY23 Established business > 20[yrs] since 1999 International peer > 600 reviewed publications IP submissions 200[+] protecting Uscom devices and technology

==> picture [24 x 35] intentionally omitted <==

==> picture [41 x 32] intentionally omitted <==

==> picture [37 x 38] intentionally omitted <==

Uscom - The Measure of Life

Uscom Ltd I FY2022 Annual FY21 Results General Meeting I uscom.com.au

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

FY22 Results

Sustained growth strategy with investment in the future

UCM Total Receipts

==> picture [339 x 222] intentionally omitted <==

----- Start of picture text -----

$5.48
$4.60
$3.64
$3.50 $3.48
$2.94 $2.86
$2.04
$1.38
$0.86 [$1.01 ]
FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22
$m AUD
----- End of picture text -----

Total Receipts impaired 35% by pandemic, Russian war, recession fears, local manufacture in China, trade wars and geopolitical tensions – Growth trend remains with expected rebound in FY23

==> picture [267 x 79] intentionally omitted <==

----- Start of picture text -----

$4.7 million $3.26 million
Cash on Hand Total Revenue
----- End of picture text -----

==> picture [39 x 39] intentionally omitted <==

$3.48 million Total annual receipts

Building the future

Response

Results

• Foxconn China local manufacture and R&D partnership

• Challenging global markets

• Total receipts impaired 35% by drop in China sales

• SE Asia boosted – Singapore HQ with BD and Sales appointment

• $4.7M cash in hand and debt free

• Expansion of distribution in China, SE Asia, Europe and US

• SE Asia, Euro, US sales substantially unchanged

• Specialised distributors for new products and pending BP+ and SpiroSonic approvals

• USCOM 1A - lead product

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Uscom Markets

Milestones

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Financial Results by Region

Uscom Total Sales by Region – FY 2022

==> picture [21 x 8] intentionally omitted <==

----- Start of picture text -----

Asia
----- End of picture text -----

==> picture [35 x 10] intentionally omitted <==

----- Start of picture text -----

Europe
----- End of picture text -----

==> picture [346 x 113] intentionally omitted <==

----- Start of picture text -----

48% 36%
of total sales of total sales
revenue revenue
----- End of picture text -----

==> picture [42 x 8] intentionally omitted <==

----- Start of picture text -----

US/Other
----- End of picture text -----

==> picture [42 x 8] intentionally omitted <==

----- Start of picture text -----

Australia
----- End of picture text -----

==> picture [352 x 113] intentionally omitted <==

----- Start of picture text -----

15% 1%
of total sales of total sales
revenue revenue
----- End of picture text -----

Sales reduced 55% due to COVID Zero and domestic manufacturing regulations, China remains Uscom’s largest market and with the Foxconn solution nearly complete and new major distributors being appointed revenue is expected to rebound strongly.

Sales were substantially unchanged despite the Russian war and COVID tail. Expansion of distributors continues and will ensure on going regional growth.

Sales were significantly increased and are expected to grow further as our expanded distribution model continues to impact the market.

The Australian market is small and sales remain modest.

Global platform for growth Hedged for currency and shifting geopolitics Global reporting, tax, transfer pricing and auditing

Uscom Ltd I FY2022 Annual FY21 Results General Meeting I uscom.com.au

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Products and Markets

High value technologies - large markets - strong predicted growth 3 high value product divisions – cardiac, hypertension/vascular and pulmonary

$21.6B USD 5yr CAGR 4.8%

==> picture [227 x 171] intentionally omitted <==

USCOM 1A

The Global Cardiac Monitoring & Cardiac Rhythm Management Market is estimated to increase from $21.6B HSD in 2020 to $27.31B USD by 2025, at a CAGR of 4.8%.

Heart failure, Sepsis, Fluid management, COVID

$1.4B USD 8yr CAGR 11.2%

==> picture [275 x 171] intentionally omitted <==

BP+

The global BP monitoring devices market is $1.4B USD and is expected to reach $5.1B USD by 2030 at a CAGR of 11.2%.

Hypertension, Vascular health

$1.3B USD 5yr CAGR 8.16%

==> picture [256 x 138] intentionally omitted <==

SpiroSonic AIR

The global spirometer market is expected to grow rom $1.269B USD in 2019 to $2.198B USD in 2026 at a CAGR of 8.16%.

Asthma, COPD, OLD, COVID

Uscom – Devices the Experts Use

Note: Researchandmarkets

Uscom Ltd I FY2022 Annual FY21 Results General Meeting I uscom.com.au

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

==> picture [134 x 90] intentionally omitted <==

SpiroSonic AIR

Next generation spirometry

“Hospital in Home” – Asthma, COVID, COPD and Occupational Lung disease Applications - Research/CRO, hospital, clinic, and eHealth home management The SpiroSonic AIR Cycle – Digital data, information, diagnosis and reports generating a cascade of revenue

==> picture [459 x 332] intentionally omitted <==

eHealth Revenue Cascade

• Device sale

• APP Sale

• Software sale

• Cloud storage - Big data

• AI analysis

• Clinician diagnosis

• Prescription

• Report

• System subscription

Digital Home Care Asthma Solution

Home care solution, digital ultrasonic AIR spirometer, BT4 digital connectivity, AIR App and software, Connected to cloud or SpiroReporter.

Revolutionising management of asthma, COPD and COVID

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

VENTITEST

The SpiroSonic VentiTest is a patent protected digital multi path ultrasonic ventilator testing and calibration solution which incorporates:

==> picture [39 x 39] intentionally omitted <==

==> picture [37 x 36] intentionally omitted <==

Low resistance

High resolution Pressure module to control piezoresistive monolithic silicon pressure sensors

bi-directional digital multipath acoustic flow monitor

==> picture [39 x 38] intentionally omitted <==

==> picture [39 x 39] intentionally omitted <==

Test lung simulator

“Weather station”

Provides variable elasticity and compliance and variable leak function to simulate the patient circulation

module for calibration of ambient temperature, pressure and humidity changes

==> picture [203 x 50] intentionally omitted <==

==> picture [141 x 237] intentionally omitted <==

==> picture [322 x 193] intentionally omitted <==

Protecting against Ventilator Induced Lung Injury – “VILI” Ventilator market $4.2B USD, with 14.7% pa growth 1 VentiTest per 10 ventilators

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

eHealth Growth

• eHealth is a health delivery revolution

• Uscom is committed to eHealth

• BlueSky eHealth expected to underwrite Uscom growth foreseeably

• First revenue for 1[st] half FY23

Global Medtech Revenues in 2019 ~$500B USD Global Medtech Growth in 2019 5.5% Global Medtech R&D in 2019 ~$31B USD

https://www.statista.com/topics/1702/medical-technology-industry/#dossierContents__outerWrapper

% 19.4 eHealth Market forecast to grow at CAGR of 19.4% for the next 7 years

==> picture [92 x 76] intentionally omitted <==

Blue Sky Uscom eHealth Ecosystem

==> picture [331 x 176] intentionally omitted <==

----- Start of picture text -----

2020 2021 2022 2023 2024 2025 2026 2027
----- End of picture text -----

eHealth market expected to grow from USD $59.60 billion in 2020 to USD $206.30 billion in 2027.

==> picture [331 x 146] intentionally omitted <==

----- Start of picture text -----

USD $206.30
USD $59.50
Billion
----- End of picture text -----

Note: Researchandmarkets

Uscom Ltd I FY2022 Annual FY21 Results General Meeting I uscom.com.au

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

International Brands

• 5 great International Brands across 3 product divisions

==> picture [883 x 321] intentionally omitted <==

----- Start of picture text -----

Blue Sky
Uscom eHealth Ecosystem
Reporter
USCOM 1A
SpiroReporter
----- End of picture text -----

Uscom - The Measure of Life

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Global Approvals

New Approvals for FY23

==> picture [938 x 293] intentionally omitted <==

----- Start of picture text -----

Regulatory Approvals
China SE Asia Euro US Russia ROW
New
• London
• Delaware • Budapest • Beijing USCOM 1A
New New 2022
• Singapore
✓ ✓
2 2023+
• Sydney
• Auckland
2023 New 2023
----- End of picture text -----

==> picture [86 x 58] intentionally omitted <==

==> picture [39 x 28] intentionally omitted <==

Regulatory approvals – expensive and unpredictable Increasingly valuable – key to revenue

==> picture [72 x 30] intentionally omitted <==

==> picture [74 x 44] intentionally omitted <==

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Publications – Clinical value

Uscom - leader in world cardiovascular and pulmonary science

==> picture [688 x 349] intentionally omitted <==

>600 Peer reviewed publications

56 Publications in FY22

25

In China in FY22

3

Global Guidelines

Applications

Emergency, Pediatrics, Cardiac transplantation, Hypertension, Electrophysiology, Heart Failure, Emergency transport, Anesthesia, Liver transplantation, ICU, Septic shock, Preeclampsia, Pulmonary hypertension, Exercise physiology, Nurse outreach, Organ procurement, Cancer, Haemodialysis, Neonates, infants, Children adults, elderly etc……..

“Saving lives worldwide”

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Uscom Devices in World’s Best Hospitals

==> picture [896 x 423] intentionally omitted <==

----- Start of picture text -----

Europe – Slovenjia – Lubiana Asia - China -
University Medical Center Europe - Poland –Lodz Chongqing
PERIN Chongqing Asia - China – Beijing
US – Chicago Europe - Italy – Roma Polish Mother’s Memorial Hospital Chilren’s Hospital Fuwai Cardiovascular Hospital
Illinois Children’s
Policlinico Casilino
Hospital Hospital Europe - Chekz Asia - China – Jinan
Europe - Italy – Padova
Rep – Praga Shandong Provincial Hospital
Policlinico - TIN Charles University
US – Pittsburgh Asia - China -
Europe - Italy – Milano
UPMC Children’s IRCCS Policlinico – Europe - Hungary – Chengdu Asia - China – Asia - China – Shanghai
Hospital Pittsburgh Clinica Mangiagalli Budapest West China Shenzhen Children’s Hospital of Shanghai
US – Cincinnatti Szent Istvan & Szenr Women’s and
Cincinnatti Children’s US – Houston Europe - Italy – Milano Laszlo Hospital Children’s Hospital Children’s HospitalShenzhen
HospitaL Texas Children’s Policlinico – Clinica De Asia - China – Shanghai
Hospital Marchi - PS Europe - Switzerland - Geneva FuDan Univeristy HuaShan Hospital
Hopiteaux Universitaire de
Geneve
Europe - Italy – Parma & Firenze Asia - China – Fujian
A.O.U. Parma & A.O.U. Careggi – Europe - Austria – Vienna Fijian Maternal and Children’s Hospital
US – LA US – St Louis Materno Infantile Medical University Asia - China -Guangzhou
Children’s Hospital of Barnes Jewish Hospital Europe - Italy – Trieste Guandong
Europe - Italy – Faenza
Los Angeles Ospedale Burlo Garofolo General Hospital Asia - China – Xiamen
Ospedale Civile – PS –
US – New York Med Urgenza Xiamen University No1 Hospital
Mount Sinai Hospital
New York Europe - Italy – Europe - Italy - – Asia - Indonesia –Jakarta
Vienna
Roma Cipto Mangankusumo
Policlinico Gemelli Medical University Hospital Oceania - Australia –
Brisbane
- TIP
US – Maine Europe - Belgium – Prince Charles Hospital
Maine General Hospital Italy – Monza Genk
Ospedale San Ziekenhuis Oost-
US – Jackson Gerardo - TIN
University of Miami Limburg Hospital Asia - Singapore – Oceania - Australia-
Sydney
Europe - Lithuania – - KK Women’s and
Vilnius S Africa Capetown Children’s St George Hospital
UCT University of Capetown
Santariskiu University
South America - Brazil Europe - Netherlands
– Sao Paulo – Maastericht S Africa – Durban Oceania - Australia – Adleaide
Instituta da Crianca, Maastricht University Ethekwinin Hospital and Heart Lyell McEwin Hospital
University Sao Paulo Hospital Centre
Uscom – Devices the Experts Use
----- End of picture text -----

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Uscom Markets

Milestones

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

IP Value

Global Assets

Next Generation Products

==> picture [525 x 30] intentionally omitted <==

----- Start of picture text -----

Registered IP Uscom Ltd Uscom China Uscom Kft Total
----- End of picture text -----

USCOM 1A	133	41	-	184
BP+	23	-	-	23
SpiroSonic	1	-	1	2
VentiTest	-	-	1	1
Total	157	41	2	200

==> picture [75 x 69] intentionally omitted <==

==> picture [68 x 66] intentionally omitted <==

==> picture [55 x 61] intentionally omitted <==

==> picture [62 x 62] intentionally omitted <==

==> picture [88 x 58] intentionally omitted <==

==> picture [141 x 28] intentionally omitted <==

==> picture [277 x 397] intentionally omitted <==

New Ideas – New Products – New value

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

US

FY22 Achievements

==> picture [78 x 58] intentionally omitted <==

==> picture [35 x 35] intentionally omitted <==

==> picture [26 x 27] intentionally omitted <==

==> picture [27 x 27] intentionally omitted <==

==> picture [26 x 27] intentionally omitted <==

Australia China Hungary Singapore

==> picture [35 x 36] intentionally omitted <==

UK

==> picture [35 x 35] intentionally omitted <==

SE Asia Hub

Singapore

Singapore regional HQ established Operational bridge between Australia and China Serving fastest growing economic region in the world Emerging financial centre of Asia

New IP and products

3 new global patent applications lodged

Ventitest (comprehensive,) Thermometric BP monitoring, Spirosonometry

==> picture [26 x 26] intentionally omitted <==

Australia

Foundation for new products for development in Beijing and global marketing

==> picture [26 x 27] intentionally omitted <==

Australia

Small Parcels Consolidation

Shareholdings of <$500 AUD value Total holdings acquired 296,199 shares acquired 129 shareholders exited the register Remaining ~860 shareholders Significantly tightening the register

==> picture [92 x 40] intentionally omitted <==

----- Start of picture text -----

November
----- End of picture text -----

==> picture [35 x 36] intentionally omitted <==

Capital Raising – In House

$4.36m raised to support capital growth and operational expansion

Subscription by Board, management and key shareholders ~5years of cash on hand to fund growth initiatives (Q3 4C)

==> picture [26 x 27] intentionally omitted <==

Australia

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

FY22 Achievements

==> picture [35 x 35] intentionally omitted <==

US

==> picture [77 x 45] intentionally omitted <==

US Regulatory

FDA Application for SpiroSonic devices US Food and Drug Administration (FDA). Multiple devices and Apps including the SpiroSonic AIR >2,000 pages of product information Clearance essential for sale into US Review proceeding

koneksa

eHealth Products

Multiple products – hedges against competition Partnership with NY Based Koneksahealth digital biomarker health monitoring for pharma Specialised connectivity and software

==> picture [35 x 35] intentionally omitted <==

US

==> picture [368 x 34] intentionally omitted <==

==> picture [27 x 27] intentionally omitted <==

Hungary

European Operations Expanding

New Sales and Marketing appointment Budapest operations restructured New French and Spanish distribution

==> picture [35 x 36] intentionally omitted <==

Sovereign Medical

Sovereign’s Medical’s mission to provide “best in class, one of a kind technology.”

East Coast US NY to Florida

3 year term, 40 devices, 12 sales specialists critical care, respiratory care, emergency medicine, sleep medicine, maternal health, and infusion therapy fields, all aspects of care Uscom devices address Underwrites profitability of US operations

==> picture [35 x 34] intentionally omitted <==

US

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

FY22 Achievements

==> picture [26 x 27] intentionally omitted <==

June

==> picture [257 x 31] intentionally omitted <==

==> picture [35 x 35] intentionally omitted <==

Singapore Expansion

Appointment of SE Asian BD and head of sales Singapore Emerging commercial centre of Asia Geopolitical neutrality and investment stability

China

Manufacturing and R&D Partnership

World’s largest precision electronics manufacturer Manufacturing, distribution and capital mandate Instant scale, reliable supply chain for Uscom Regulatory and distribution connections Manufacturing and R&D premises in Beijing USCOM 1A and 3 other devices for registration and manufacture

==> picture [93 x 40] intentionally omitted <==

----- Start of picture text -----

April
----- End of picture text -----

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Foxconn Partnership

==> picture [264 x 32] intentionally omitted <==

Worlds largest precision electronics manufacturer

==> picture [489 x 324] intentionally omitted <==

Uscom’s new Beijing manufacturing facility with the first trial devices for assembly

>40% of all global precision electronics

• World’s largest precision electronic manufacturer

• Operations in >20 countries, and 12 manufacturing centres in China

• Largest single employer in China with >1.3m employees worldwide

Manufacturing, distribution and investment mandates

• New focus on sophisticated medical technology

• • Uscom has >40 IP cases in China and >200 worldwide

• Cost-effective manufacture and reliable supply chain

Global revenue ~$300B AUD

• Instant manufacturing scale for Uscom.

• High medical technology partner for Foxconn.

• Uscom manufacturing and R&D centre

• Expansion of Foxconn Technology Industry Zone in Beijing

Partners

• Uscom, Apple, Huawei, Xiaomi, Amazon, Sony, Toshiba, Microsoft, Intel, Google, etc.

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

China Connection

“China is large, growing and with a special focus on advanced medical technology”

China Recognition

Guangdong Collaboration

Collaboration Professor Shao-Ru He Department of Neonatology, Guangdong General Hospital

COVID Method

Recommended method for COVID-19 treatment by Chinese National Health and Medical Commission

==> picture [110 x 74] intentionally omitted <==

China National High Technology Enterprise (MOST) and AAA Credit Enterprise

~50 Chinese IP applications

Foxconn partnership

25 Chinese publications in 2022

==> picture [886 x 62] intentionally omitted <==

----- Start of picture text -----

2003 2011 2018 2020 2021
----- End of picture text -----

==> picture [73 x 108] intentionally omitted <==

Regulatory Approval

SARS-CoV fast track regulatory approval

ASX Listed - UCM

Uscom China

Uscom China established in Beijing

==> picture [121 x 79] intentionally omitted <==

installed in >50 infectious disease centres in China >500 units installed nationally

150 national/provincial lectures/collaborations

ED Guidelines for Heart Failure

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Two Step Revenue Strategy

Products: USCOM 1A

New Products:

• USCOM Maternal

• USCOM v1

• USCOM v2

• USCOM v3

• USCOM v4

• ...

Software/Consumables:

• CardioCare

• Consumable 1

• Consumable 2

• Consumable 3

• Consumable 4

• …

==> picture [187 x 27] intentionally omitted <==

----- Start of picture text -----

USCOM 1A
----- End of picture text -----

Products: BP+ & BP+ Reporter

New Products:

• BP+

• BP+ v2

• BP+ v3

• ...

Software/Consumables:

• BP+ Reporter

• Disposable - 10

• BP+ 2

• …

==> picture [187 x 27] intentionally omitted <==

----- Start of picture text -----

BP+
----- End of picture text -----

Products: SpiroSonic FLO, SMART, MOBILE, SpiroReporter

New Products:

• SpiroSonic AIR

• SpiroSonic PRO

• SpiroSonic v2

• ...

Software/Consumables:

• SpiroReporter v2

• SpiroFilter

• Disinfectant

• SpiroSonic APP – SA1 and SA2

• VentiTest - S

• … SpiroSonic

==> picture [160 x 198] intentionally omitted <==

----- Start of picture text -----

Step 2
$30m
Step 1
$10m
$5m
2023 2025 2027
----- End of picture text -----

Two Steps Strategy

Current revenue * (~$5M) USCOM 1A global SpiroSonic Europe Step 1 revenue (~$10M) USCOM 1A Global SpiroSonic Global BP+ Worldwide

Step 2 revenue ($?30M) Step 1 + 10 new products, consumables and global markets

• Current revenue

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

FY23 Regional Growth Strategy

==> picture [35 x 35] intentionally omitted <==

==> picture [35 x 36] intentionally omitted <==

==> picture [27 x 27] intentionally omitted <==

==> picture [26 x 27] intentionally omitted <==

==> picture [26 x 27] intentionally omitted <==

Australia Singapore China Hungary UK

==> picture [35 x 35] intentionally omitted <==

US

Uscom SE Asia

Singapore new operational focus linking SE Asia, China and Australia Regional HQ for distribution and regulatory for USCOM 1A, SpiroSonic and BP+. Expand regional distribution and sales

Uscom China

Develop domestic manufacture with Foxconn Establish operations of scale

Prepare BP+ and SpiroSonic marketing and distribution.

Develop new products for manufacture

Uscom Europe

Increase R&D and manufacturing capacity

Increasing distribution and sales for USCOM 1A, BP+ and SpiroSonic New operations and partners

Uscom US

Activate new distribution model to meet post pandemic demand Prepare for SpiroSonic and BP+ FDA

Develop eHealth strategic partnerships

Uscom – Global Growth

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Uscom Value

Advanced Global Medtech Company

Great company, with great vision, technology, culture and global opportunity Expanding international sales Established global operations.

Flagship Technologies

Flagship technologies in prestige cardiovascular and pulmonary sector.

10 year CAGR growth trend

Total Receipts $3.48m AUD)) Debt free with cash on hand $4.7m AUD Growth drivers poised.

Impending value drivers

Foxconn partnership, 10 new products, US distribution, China and US regulatory approvals, European distribution, SE Asia distribution, China “MIC 25” compliant.

01

06

==> picture [89 x 145] intentionally omitted <==

----- Start of picture text -----

02
----- End of picture text -----

Acquisition and Integration

05

Acquisition and integration of two international med tech companies Incremental growth.

==> picture [145 x 111] intentionally omitted <==

----- Start of picture text -----

04
----- End of picture text -----

==> picture [143 x 110] intentionally omitted <==

----- Start of picture text -----

03
----- End of picture text -----

Deep IP and academic recognition

200+ IP submissions

Multiple Uscom devices and technology, >600 Peer reviewed papers.

Uscom - The Measure of Life

Uscom Overview

FY23 Outlook

Chair's Update

FY22 Results

Milestones

Uscom Markets

Uscom Ltd I FY2022 Annual General Meeting I uscom.com.au

Summary

“A great company, with great vision, technology and culture, and a great global opportunity”

FY22

Continued growth and investment despite challenging business conditions More products, more distribution, cash on hand, and debt free, global growth strategy

FY23

New products, advanced regulatory approvals, expanded global operations and distribution, registered new IP, and established a new transformational manufacturing and R&D partnership that will underwrite future growth. Cash on hand and prepared to leverage off global rebound in FY23, Prepared for international partnerships of scale and value

Uscom has never been in a better position…..

Corporate Responsibility

==> picture [78 x 93] intentionally omitted <==

==> picture [195 x 60] intentionally omitted <==

==> picture [87 x 36] intentionally omitted <==

==> picture [182 x 45] intentionally omitted <==

Thank You ASX: UCM

Prof. Rob Phillips Chairman and CEO, Uscom Limited

Nov 10,2022